BARDA continues to expand pool of CROs

The exclusive contractors club adds two new global CROs as it continues to expand capabilities amid the Covid-19 pandemic.

Pharm-Olam and PRA Health have become the latest contract research organisations to join the Biomedical Advanced Research and Development Authority’s (BARDA) Clinical Studies Network, an exclusive club of research companies responsible for the procurement and development of medical countermeasures in the United States.

When BARDA was founded in 2012, contracts were sent out to a handful of CROs that were brought onboard to assist getting new drugs and vaccines approved at speed when needed such as during public health emergencies. However, the CROs within the network were often seen as incapable of sufficiently responding to demand, hence measures were taken to expand the network.